| Year |
Citation |
Score |
| 2017 |
Blieden M, Gandra SR, Cheng LI, Szatkowski A, Toth PP. Differences in utility elicitation methods in cardiovascular disease: a systematic review. Journal of Medical Economics. 1-23. PMID 28899233 DOI: 10.1080/13696998.2017.1379410 |
0.325 |
|
| 2017 |
Rosenson RS, Gandra SR, McKendrick J, Dent R, Wieffer H, Cheng LI, Catapano AL, Oh P, Kees Hovingh G, Stroes ES. Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. Cardiovascular Drugs and Therapy. PMID 28466399 DOI: 10.1007/S10557-017-6727-0 |
0.386 |
|
| 2017 |
Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A, Hout BV. Cost-Effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical Therapeutics. PMID 28366593 DOI: 10.1016/J.Jval.2016.09.1755 |
0.385 |
|
| 2017 |
Punekar RS, Fox KM, Paoli CJ, Richhariya A, Cziraky MJ, Gandra SR, Toth PP. Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. Current Medical Research and Opinion. 1-8. PMID 28276256 DOI: 10.1080/03007995.2017.1292898 |
0.407 |
|
| 2017 |
Deshpande S, Quek RG, Forbes CA, de Kock S, Kleijnen J, Gandra SR, Simpson RJ. A systematic review to assess the adherence and persistence with statins. Current Medical Research and Opinion. 1-23. PMID 28076703 DOI: 10.1080/03007995.2017.1281109 |
0.329 |
|
| 2016 |
Burke JP, Simpson RJ, Paoli CJ, McPheeters JT, Gandra SR. Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy. Journal of Clinical Lipidology. 10: 1470-1480.e3. PMID 27919365 DOI: 10.1016/J.Jacl.2016.09.002 |
0.397 |
|
| 2016 |
Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR. Productivity losses associated with cardiovascular disease: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research. PMID 27831848 DOI: 10.1080/14737167.2016.1259571 |
0.342 |
|
| 2016 |
Wei CY, Quek RG, Villa G, Gandra SR, Forbes CA, Ryder S, Armstrong N, Deshpande S, Duffy S, Kleijnen J, Lindgren P. A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. Pharmacoeconomics. PMID 27785772 DOI: 10.1007/S40273-016-0464-2 |
0.327 |
|
| 2016 |
Nicholson G, Gandra SR, Halbert RJ, Richhariya A, Nordyke RJ. Patient-level costs of major cardiovascular conditions: a review of the international literature. Clinicoeconomics and Outcomes Research : Ceor. 8: 495-506. PMID 27703385 DOI: 10.2147/Ceor.S89331 |
0.382 |
|
| 2016 |
Forbes CA, Quek RG, Deshpande S, Worthy G, Wolff R, Stirk L, Kleijnen J, Gandra SR, Djedjos S, Wong ND. The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids in Health and Disease. 15: 95. PMID 27184891 DOI: 10.1186/S12944-016-0258-8 |
0.305 |
|
| 2016 |
Zhao Y, Delaney JA, Quek RG, Gardin JM, Hirsch CH, Gandra SR, Wong ND. Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults. Clinical Cardiology. PMID 27177347 DOI: 10.1002/Clc.22546 |
0.305 |
|
| 2016 |
Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, van Hout B. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology. PMID 27092712 DOI: 10.1016/J.Jval.2016.03.029 |
0.383 |
|
| 2016 |
Forbes C, Quek RG, Deshpande S, Worthy G, Ross J, Kleijnen J, Gandra SR, Kassahun H, Wong ND, Nicholls SJ. Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: A systematic literature review. Current Medical Research and Opinion. 1-31. PMID 26949994 DOI: 10.1185/03007995.2016.1162775 |
0.304 |
|
| 2016 |
Unni SK, Quek RG, Biskupiak J, Lee VC, Ye X, Gandra SR. Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States. Journal of Clinical Lipidology. 10: 63-71.e3. PMID 26892122 DOI: 10.1016/J.Jacl.2015.09.008 |
0.405 |
|
| 2016 |
Hallberg S, Banefelt J, Fox KM, Mesterton J, Johansson G, Levin LÅ, Sobocki P, Gandra SR. Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden. International Journal of Clinical Practice. 70: 222-8. PMID 26799539 DOI: 10.1111/Ijcp.12769 |
0.368 |
|
| 2016 |
Fox KM, Wang L, Gandra SR, Quek RG, Li L, Baser O. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study. Bmc Cardiovascular Disorders. 16: 13. PMID 26769473 DOI: 10.1186/S12872-016-0190-X |
0.409 |
|
| 2016 |
Hovingh GK, Gandra SR, McKendrick J, Dent R, Wieffer H, Catapano AL, Oh P, Rosenson RS, Stroes ES. Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. Atherosclerosis. 245: 111-7. PMID 26717273 DOI: 10.1016/J.Atherosclerosis.2015.12.015 |
0.395 |
|
| 2016 |
Punekar RS, Fox K, Richhariya A, Gandra S, Cziraky M, Paoli C, Toth P. TRENDS IN REAL-WORLD TREATMENT MODIFICATIONS AMONG HIGH-CARDIOVASCULAR DISEASE RISK PATIENTS WITH HYPERLIPIDEMIA Journal of the American College of Cardiology. 67: 1923. DOI: 10.1016/S0735-1097(16)31924-6 |
0.386 |
|
| 2016 |
Rosenson R, McKendrick J, Gandra S, Dent R, Wieffer H, Catapano A, Oh P, Hovingh G, Stroes E. Management of Patients with Statin Intolerance: Results from a Survey of Clinicians in Six European Countries Value in Health. 19: A664. DOI: 10.1016/J.Jval.2016.09.1828 |
0.33 |
|
| 2016 |
Rosenson R, Gandra S, McKendrick J, Dent R, Wieffer H, Catapano A, Oh P, Hovingh G, Stroes E. Identification and Management of Patients with Statin Intolerance in Saudi Arabia and the United Arab Emirates: Comparison of Results from a Clinician Survey Value in Health. 19: A664. DOI: 10.1016/J.Jval.2016.09.1827 |
0.345 |
|
| 2016 |
Blieden M, Szatkowski A, Cheng L, Gandra S. A Systematic Review Comparing Studies of Cardiovascular Event Utilities by Geographic Region Value in Health. 19: A869. DOI: 10.1016/J.Jval.2016.08.375 |
0.305 |
|
| 2016 |
Kajinami K, McKendrick J, Gandra S, Cheng L, Hovingh G, Dent R, Wieffer H, Catapano A, Oh P, Rosenson R, Stroes E. Management of Patients with Statin Intolerance in Japan, South Korea and Taiwan: Comparison of Results From A Clinician Survey Value in Health. 19: A872. DOI: 10.1016/J.Jval.2016.08.365 |
0.339 |
|
| 2016 |
Quek R, Hardin J, Bonafede M, Johnson B, Gandra S. Use Of Real-World Data To Estimate Cardiovascular Event Rates Among Non-Elderly Commercially Insured High Cardiovascular Risk Patients In The United States Value in Health. 19: A11. DOI: 10.1016/J.Jval.2016.03.257 |
0.352 |
|
| 2016 |
Quek R, Hardin J, Bonafede M, Johnson B, Gandra S. Use Of Real-World Data To Estimate Cardiovascular Event Rates Among Elderly High Cardiovascular Risk Patients With Medicare Supplemental Insurance In The United States Value in Health. 19: A11. DOI: 10.1016/J.Jval.2016.03.256 |
0.353 |
|
| 2016 |
Blieden M, Szatkowski A, Cheng L, Paoli C, Gandra S. How do utilities vary for cardiovascular events? A systematic review Value in Health. 19: A51. DOI: 10.1016/J.Jval.2016.03.169 |
0.315 |
|
| 2016 |
Rosenson R, Gandra S, McKendrick J, Dent R, Wieffer H, Catapano A, Oh P, Hovingh G, Stroes E. Identifying and Managing Patients with Symptoms of Statin Intolerance: Results from a Survey of Clinicians in the United States Value in Health. 19: A53. DOI: 10.1016/J.Jval.2016.03.130 |
0.313 |
|
| 2016 |
McKendrick J, Gandra S, Hovingh G, Dent R, Wieffer H, Catapano A, Oh P, Rosenson R, Stroes E. Identification and Management of Patients with Symptoms of Statin Intolerance: Results from A Survey of Brazilian Clinicians Value in Health. 19: A53. DOI: 10.1016/J.Jval.2016.03.127 |
0.307 |
|
| 2016 |
Bonafede M, Johnson B, Paoli C, Gandra S. Annual Fatal and Non-Fatal Cardiovascular Event Costs among Non-Elderly Commercially Insured Adults with Hyperlipidemia in the United States Value in Health. 19: A46. DOI: 10.1016/J.Jval.2016.03.104 |
0.317 |
|
| 2016 |
Quek R, Forbes C, Deshpande S, Worthy G, Wolff R, Stirk L, Kleijnen J, Gandra S, Djedjos S, Wong N. Relationship between Lipoprotein(A) and Cardiovascular Events: A Systematic Review Value in Health. 19: A43. DOI: 10.1016/J.Jval.2016.03.086 |
0.317 |
|
| 2016 |
Hardin J, Quek R, Roehl K, Richhariya A, Gandra S. Use of Real-World Data to Estimate Prevalence of Commercially-Insured High Cardiovascular Risk Patients in the United States Value in Health. 19: A42-A43. DOI: 10.1016/J.Jval.2016.03.085 |
0.339 |
|
| 2016 |
Oh P, Hovingh G, Gandra S, McKendrick J, Dent R, Wieffer H, Catapano A, Rosenson R, Stroes E. Identification and Management of Canadian Patients with Symptoms of Statin Intolerance: Results from a Real-World Clinical Practice Survey Value in Health. 19: A53. DOI: 10.1016/J.Atherosclerosis.2016.07.156 |
0.301 |
|
| 2015 |
Quek RG, Fox KM, Wang L, Li L, Gandra SR, Wong ND. A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event. The American Journal of Cardiology. PMID 26742468 DOI: 10.1016/J.Amjcard.2015.11.035 |
0.422 |
|
| 2015 |
Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, Levin LÅ, Sobocki P, Gandra SR. Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. PMID 26607457 DOI: 10.1007/S10198-015-0749-Y |
0.403 |
|
| 2015 |
Henk HJ, Paoli CJ, Gandra SR. A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia. Advances in Therapy. 32: 1104-16. PMID 26585336 DOI: 10.1007/S12325-015-0264-7 |
0.383 |
|
| 2015 |
Blieden M, Smith D, Becker BT, Paoli CJ, Gandra SR. A Systematic Review Of Cardiovascular Event Utilities In Europe. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A397. PMID 26532239 DOI: 10.1016/J.Jval.2015.09.904 |
0.317 |
|
| 2015 |
Quek RG, Fox KM, Wang L, Li L, Gandra SR, Wong ND. Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. Bmj Open Diabetes Research & Care. 3: e000132. PMID 26435839 DOI: 10.1136/Bmjdrc-2015-000132 |
0.393 |
|
| 2015 |
Song X, Quek RG, Gandra SR, Cappell KA, Fowler R, Cong Z. Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures. Bmc Health Services Research. 15: 245. PMID 26104784 DOI: 10.1186/S12913-015-0925-X |
0.404 |
|
| 2015 |
Punekar RS, Fox KM, Richhariya A, Fisher MD, Cziraky M, Gandra SR, Toth PP. Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia. Clinical Cardiology. 38: 483-91. PMID 26100722 DOI: 10.1002/Clc.22428 |
0.394 |
|
| 2015 |
Bonafede MM, Johnson BH, Richhariya A, Gandra SR. Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia. Clinicoeconomics and Outcomes Research : Ceor. 7: 337-45. PMID 26089693 DOI: 10.2147/Ceor.S76972 |
0.372 |
|
| 2015 |
Hallberg S, Gandra SR, Fox KM, Mesterton J, Banefelt J, Johansson G, Levin LÅ, Sobocki P. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. PMID 26077550 DOI: 10.1007/S10198-015-0702-0 |
0.348 |
|
| 2015 |
Matza LS, Stewart KD, Gandra SR, Delio PR, Fenster BE, Davies EW, Jordan JB, Lothgren M, Feeny DH. Acute and chronic impact of cardiovascular events on health state utilities. Bmc Health Services Research. 15: 173. PMID 25896804 DOI: 10.1186/S12913-015-0772-9 |
0.309 |
|
| 2015 |
Nicholson G, Paoli C, Gandra S. Systematic Litertaure Review Of Direct Health Care Costs For Cardiovascular Events Among European Patients With Dyslipidemia Or High Cardiovascular Risk Value in Health. 18: A387. DOI: 10.1016/J.Jval.2015.09.849 |
0.409 |
|
| 2015 |
Fox K, Wang L, Gandra S, Quek R, Li L, Baser O. Long-Term Economic Burden Associated With Cardiovascular Events Among High-Risk Patients With Hyperlipidemia Value in Health. 18: A139-A140. DOI: 10.1016/J.Jval.2015.03.811 |
0.34 |
|
| 2015 |
Paoli C, Gandra S, Henk H. Acute, Short-Term And Long-Term Costs Of Cardiovascular Events Among Hyperlipidemia Patients Value in Health. 18: A138-A139. DOI: 10.1016/J.Jval.2015.03.806 |
0.306 |
|
| 2015 |
Paoli CJ, Bonafede M, Gandra S, Cappell K, Simpson RJ. Trends in Treatment Patterns of First Statin and Ezetimibe Use in the United States from 2007-2012 Journal of Clinical Lipidology. 9: 473. DOI: 10.1016/J.Jacl.2015.03.098 |
0.329 |
|
| 2014 |
Hallberg S, Banefelt J, Fox KM, Mesterton J, Johansson G, Levin LÅ, Sobocki P, Gandra SR. Treatment Patterns in Hyperlipidemia Patients With New Cardiovascular Events - Estimates From Population-Based Register Data in Sweden. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A501. PMID 27201519 DOI: 10.1016/J.Jval.2014.08.1507 |
0.349 |
|
| 2014 |
Hallberg S, Banefelt J, Mesterton J, Gandra SR, Fox KM, Johansson G, Levin LÅ, Sobocki P. Health Care Costs Associated With Cardiovascular Events In Patients With Hyperlipidemia - Estimates From Population-Based Register Data In Sweden. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A492. PMID 27201468 DOI: 10.1016/J.Jval.2014.08.1455 |
0.388 |
|
| 2014 |
Schmid T, Xu W, Gandra SR, Michailov G. Costs Of Treating Cardiovascular Events In Germany: A Systematic Literature Review. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A485. PMID 27201428 DOI: 10.1016/J.Jval.2014.08.1418 |
0.343 |
|
| 2014 |
Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, Levin LÅ, Sobocki P, Gandra SR. Work Productivity Loss and Indirect Costs Associated with New Cardiovascular Events in High-Risk Patients with Hyperlipidemia - Estimates from Population-Based Register Data in Sweden. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A327-8. PMID 27200553 DOI: 10.1016/J.Jval.2014.08.596 |
0.361 |
|
| 2014 |
Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Advances in Therapy. 31: 410-25. PMID 24604700 DOI: 10.1007/S12325-014-0110-3 |
0.309 |
|
| 2014 |
Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans. Journal of Medical Economics. 17: 1-10. PMID 24131136 DOI: 10.3111/13696998.2013.856314 |
0.331 |
|
| 2013 |
Hone D, Cheng A, Watson C, Huang B, Bitman B, Huang XY, Gandra SR. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care & Research. 65: 1564-72. PMID 23554320 DOI: 10.1002/Acr.22022 |
0.324 |
|
| 2013 |
Fisher MD, Watson C, Fox KM, Chen YW, Gandra SR. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Current Medical Research and Opinion. 29: 561-8. PMID 23489410 DOI: 10.1185/03007995.2013.786693 |
0.358 |
|
| 2013 |
Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. The Journal of Dermatological Treatment. 24: 369-73. PMID 23441722 DOI: 10.3109/09546634.2012.755255 |
0.353 |
|
| 2013 |
Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. The Journal of Dermatological Treatment. 24: 25-33. PMID 22668321 DOI: 10.3109/09546634.2012.661038 |
0.348 |
|
| 2013 |
Schabert V, Fox K, Watson C, Yeaw J, Goodman S, Gandra S. AB0499 Post-discontinuation treatment patterns for tumor necrosis factor-blockers in rheumatoid arthritis patients in the US Annals of the Rheumatic Diseases. 71: 666.8-666. DOI: 10.1136/Annrheumdis-2012-Eular.499 |
0.306 |
|
| 2013 |
Blume S, Fox K, Joseph G, Chuang C, Thomas J, Gandra S. AB0496 Tumor necrosis factor (TNF)-inhibitor dose escalation in rheumatoid arthritis (RA) patients in a united states (US) pharmacy benefits management (PBM) setting: Annals of the Rheumatic Diseases. 71: 666.5-666. DOI: 10.1136/Annrheumdis-2012-Eular.496 |
0.327 |
|
| 2013 |
Stuart M, Shrite S, Gandra S. AB0478 Systematic safety review of five biologic antirheumatic drugs: Annals of the Rheumatic Diseases. 71: 665.2-665. DOI: 10.1136/Annrheumdis-2012-Eular.478 |
0.359 |
|
| 2013 |
Fisher M, Watson C, Fox K, Chen Y, Gandra S. SAT0143 Tumor necrosis factor-blocker use in us managed care: Utilization and dosing patterns among rheumatoid arthritis patients: Annals of the Rheumatic Diseases. 71: 520.1-520. DOI: 10.1136/Annrheumdis-2012-Eular.3090 |
0.37 |
|
| 2013 |
Nicholson G, Halbert R, Nordyke R, Willis V, Siemak B, Richhariya A, Gandra S. Patient-Level Costs of Cardiovascular Events and Procedures: How Robust Is the Evidence? Value in Health. 16: A522. DOI: 10.1016/J.Jval.2013.08.1259 |
0.356 |
|
| 2012 |
Chastek B, Fox KM, Watson C, Gandra SR. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Advances in Therapy. 29: 691-7. PMID 22903239 DOI: 10.1007/S12325-012-0039-3 |
0.345 |
|
| 2012 |
Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Advances in Therapy. 29: 664-74. PMID 22886712 DOI: 10.1007/S12325-012-0037-5 |
0.305 |
|
| 2012 |
Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Advances in Therapy. 29: 234-48. PMID 22411424 DOI: 10.1007/S12325-012-0007-Y |
0.415 |
|
| 2012 |
Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. Journal of Medical Economics. 15: 635-43. PMID 22332705 DOI: 10.3111/13696998.2012.667028 |
0.326 |
|
| 2012 |
Bonafede MM, Fox KM, Johnson BH, Watson C, Gandra SR. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clinical Therapeutics. 34: 457-67. PMID 22284901 DOI: 10.1016/J.Clinthera.2011.12.016 |
0.354 |
|
| 2012 |
Fox KM, Yee J, Cong Z, Brooks JM, Petersen J, Lamerato L, Gandra SR. Transfusion burden in non-dialysis chronic kidney disease patients with persistent anemia treated in routine clinical practice: a retrospective observational study. Bmc Nephrology. 13: 5. PMID 22273400 DOI: 10.1186/1471-2369-13-5 |
0.328 |
|
| 2012 |
Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. Journal of Medical Economics. 15: 264-75. PMID 22115327 DOI: 10.3111/13696998.2011.644645 |
0.363 |
|
| 2012 |
Varni JW, Globe DR, Gandra SR, Harrison DJ, Hooper M, Baumgartner S. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. European Journal of Pediatrics. 171: 485-92. PMID 21960290 DOI: 10.1007/S00431-011-1587-2 |
0.329 |
|
| 2012 |
Fisher M, Watson C, Gandra S, Chen Y, Fox K. PMS70 Tumor Necrosis Factor (TNF)-Blocker Dose Escalation among Patients with Rheumatoid Arthritis (RA) in a Large Managed Care Population in the United States Value in Health. 15: A46. DOI: 10.1016/J.Jval.2012.03.259 |
0.326 |
|
| 2012 |
Bonafede M, Gandra SR, Fox KM, Wilson K. PMS69 Tumor Necrosis Factor Blocker Dose Escalation among Biologic Naïve Rheumatoid Arthritis (RA) Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.258 |
0.327 |
|
| 2012 |
Bonafede M, Gandra S, Watson C, Princic N, Fox K. PMS23 Cost Per Treated Rheumatoid Arthritis (RA) Patient for Etanercept, Adalimumab and Infliximab: A Retrospective Claims Database Analysis Value in Health. 15: A37. DOI: 10.1016/J.Jval.2012.03.212 |
0.321 |
|
| 2012 |
Bonafede M, Watson C, Gandra S, Princic N, Fox K. PMS16 Cost of Tumor Necrosis Factor Blocker Per Treated Psoriatic Arthritis Patient Using Drug Utilization Data from a US Managed Care Population Value in Health. 15: A36. DOI: 10.1016/J.Jval.2012.03.205 |
0.353 |
|
| 2011 |
Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, Gandra SR, Solomon SD, Moustafa M, Macdougall IC, Locatelli F, Parfrey PS. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of the American Society of Nephrology : Cjasn. 6: 845-55. PMID 21212421 DOI: 10.2215/Cjn.06450710 |
0.331 |
|
| 2011 |
Schabert V, Gandra S, Watson C, Fox K, Yeaw J, Goodman S, Milev S, Harrison D. PMS15 Costs of Tumor Necrosis Factor Blockers per Treated Patient Across Adult Indications Using Real-World Data in US Commercially-Insured Population Value in Health. 14: A304-A305. DOI: 10.1016/J.Jval.2011.08.401 |
0.326 |
|
| 2011 |
Bonafede M, Gandra S, Watson C, Princic N, Fox K. PMS14 Cost of Etanercept, Adalimumab, and Infliximab Per Treated Patient Across Adult Indications Using Real-World Data Value in Health. 14: A304. DOI: 10.1016/J.Jval.2011.08.400 |
0.332 |
|
| 2011 |
Gandra S, Vernon M, Cole J, Bitman B, Park G, Wang B, Chaudhari S, Fleischmann R. PMS44 ASSESSING VITALITY IN PATIENTS UNDERGOING ETANERCEPT THERAPY FOR RHEUMATOID ARTHRITIS Value in Health. 14: A131. DOI: 10.1016/J.Jval.2011.02.729 |
0.316 |
|
| 2011 |
Bonafede M, Johnson B, Fox K, Watson C, Gandra S. PMS3 RISK FACTORS FOR NON-INITIATION OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARD) BY PATIENTS WITH NEWLY DIAGNOSED RHEUMATOID ARTHRITIS (RA) Value in Health. 14: A123. DOI: 10.1016/J.Jval.2011.02.689 |
0.301 |
|
| 2010 |
Sharma A, Yee J, Gandra SR, Khan I, Petersen J. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Current Medical Research and Opinion. 26: 2679-87. PMID 20942616 DOI: 10.1185/03007995.2010.526598 |
0.308 |
|
| 2010 |
Keown PA, Churchill DN, Poulin-Costello M, Lei L, Gantotti S, Agodoa I, Gitlin M, Gandra SR, Mayne TJ. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodialysis International. International Symposium On Home Hemodialysis. 14: 168-73. PMID 20345390 DOI: 10.1111/J.1542-4758.2009.00422.X |
0.315 |
|
| 2010 |
Seliger S, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker L, Chiou CF, Fink JC. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clinical Journal of the American Society of Nephrology : Cjasn. 5: 882-8. PMID 20299377 DOI: 10.2215/Cjn.07171009 |
0.316 |
|
| 2010 |
Miller M, Bennett AV, Gandra SR, Lewis EF, Martin ML, Patrick DL. 195: Symptoms and Impacts Reported By Patients With Type 2 Diabetes and Nondialysis Chronic Kidney Disease Related Anemia American Journal of Kidney Diseases. 55: B80. DOI: 10.1053/J.Ajkd.2010.02.202 |
0.303 |
|
| 2009 |
Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. Journal of Managed Care Pharmacy : Jmcp. 15: 741-50. PMID 19954265 DOI: 10.18553/Jmcp.2009.15.9.741 |
0.34 |
|
| 2008 |
Martin ML, Patrick DL, Bushnell DM, Gandra SR, Gilchrist K. Further validation of an individualized migraine treatment satisfaction measure. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 904-12. PMID 18494756 DOI: 10.1111/J.1524-4733.2008.00320.X |
0.323 |
|
| 2006 |
Gandra SR, Lawrence LW, Parasuraman BM, Darin RM, Sherman JJ, Wall JL. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. Journal of Managed Care Pharmacy : Jmcp. 12: 546-54. PMID 16981800 DOI: 10.18553/Jmcp.2006.12.7.546 |
0.717 |
|
| 2004 |
Lawrence L, Sherman J, Adams E, Gandra S. Pharmacy Students' Perceptions of Pharmaceutical Care in Retail and Clinic Settings American Journal of Pharmaceutical Education. 68: 4. DOI: 10.5688/Aj680104 |
0.694 |
|
| 2004 |
Gandra S, Parasuraman B, Lawrence L, Humble L. Pmc22 Review Of Instruments Measuring Treatment Satisfaction With Medication Value in Health. 7: 775. DOI: 10.1016/S1098-3015(10)66069-X |
0.69 |
|
| Show low-probability matches. |